Core Insights - The collaboration between Aihuilong and Sanofi marks a significant shift in diabetes management in China, transitioning from passive treatment to proactive intervention for Type 1 diabetes [2][3] - This partnership aims to create an integrated diagnostic and treatment solution, enhancing clinical decision-making through precise detection and innovative medication [2][3] Group 1: Industry Impact - The collaboration is expected to establish a comprehensive clinical management system for Type 1 diabetes, combining Aihuilong's diagnostic capabilities with Sanofi's innovative therapies [2] - The initiative is seen as a breakthrough in the refined management of chronic diseases in China, particularly in identifying high-risk populations and assessing pancreatic function dynamically [2] Group 2: Patient Benefits - By facilitating early screening and precise intervention, the partnership aims to provide patients and their families with a valuable "buffer period," allowing for smoother transitions through critical life stages [3] - The integration of diagnostics and treatment is positioned as a model for future healthcare collaborations, optimizing the management pathway from risk screening to innovative treatment [3]